ivermectin - versus potential COVID-19 treatments - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.40 [0.13, 1.23]< 10%3 studies (3/-)94.4 %some concernnot evaluable moderatecrucial-
deaths 0.66 [0.44, 1.00]< 10%10 studies (10/-)97.4 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.94 [0.51, 1.73]< 10%1 study (1/-)57.9 %NAnot evaluable crucial-
clinical deterioration 0.66 [0.32, 1.34]< 169%4 studies (4/-)87.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.67 [1.05, 2.66]> 10%3 studies (3/-)98.5 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.26 [0.68, 2.32]> 182%3 studies (3/-)77.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %NAnot evaluable important-
death or ventilation 0.89 [0.30, 2.64]< 10%1 study (1/-)58.4 %NAnot evaluable important-
hospital discharge 1.25 [0.80, 1.95]> 10%3 studies (3/-)83.7 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.45 [0.22, 0.95]< 10%6 studies (6/-)98.2 %some concernnot evaluable moderateimportant-
viral clearance 0.93 [0.78, 1.10]> 10%2 studies (2/-)19.3 %lownot evaluable highimportant-
viral clearance (time to event analysis only) 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %NAnot evaluable important-
viral clearance by day 14 3.54 [1.03, 12.13]> 10%2 studies (2/-)97.8 %highnot evaluable lowimportant-
viral clearance by day 7 1.44 [0.69, 3.00]> 183%4 studies (4/-)83.7 %some concernnot evaluable moderateimportant-
ICU admission 1.10 [0.64, 1.86]< 10%3 studies (3/-)36.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.49 [0.20, 10.91]< 10%3 studies (3/-)34.8 %some concernnot evaluable moderateimportant-
adverse events 1.52 [0.72, 3.24]< 110%4 studies (4/-)13.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.